Form 4: Disc Medicine CMO Sells Shares Under 10b5-1 Plan

Disc Medicine's Chief Medical Officer, William Jacob Savage, sold 7,378 shares of common stock on March 2, 2026, through a pre-arranged 10b5-1 trading plan.

Summary

• William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc., sold a total of 7,378 shares of common stock.
• The sales occurred on March 2, 2026.
• 4,392 shares were sold at a weighted average price of $65.5218, with prices ranging from $65.00 to $65.98.
• An additional 2,986 shares were sold at a weighted average price of $66.409, with prices ranging from $66.03 to $66.88.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on October 2, 2025.
• Following these transactions, the reporting person beneficially owns 85,211 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale reduces direct ownership, its execution under a pre-arranged 10b5-1 plan mitigates concerns about immediate negative sentiment from the insider.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to negative company-specific news.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake in the company.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider sales, particularly by C-suite executives in the biotech sector, are closely watched for signals regarding company performance or future prospects. However, sales executed under a 10b5-1 plan are generally viewed as less indicative of a change in sentiment compared to open market sales, as they are pre-scheduled.

Related Party Transactions

• The transactions involve an officer of the company, which is a related party transaction, but it is a standard insider trading disclosure.

Stakeholder Impact

• Shareholders: May interpret the sale as a slight negative due to reduced insider ownership, though the 10b5-1 plan context lessens this impact.

Key Dates

Recommendation

The insider sale by the Chief Medical Officer, while reducing his direct stake, was conducted under a pre-arranged 10b5-1 plan. This suggests a planned liquidity event rather than a reaction to new company-specific information. Without additional context on company performance or strategic developments, this event alone does not warrant a change from a 'hold' position. Investors should monitor future filings and company news for more substantive indicators.

Keywords

Disc Medicine, IRON, Form 4, Insider Sale, William Jacob Savage, Chief Medical Officer, 10b5-1 Plan, Equity Transaction